Kiadis Pharma NV (KDS) EUR0.10
Kiadis Pharma NV is a clinical stage biopharmaceutical company based in the Netherlands. It focuses on research and development of cell-based immunotherapy products for the treatment of blood cancer (leukemia) and inherited blood disorders, such as thalassemia. The Company develops products that provide for Allodepleted T-cell ImmunotheRapeutics (ATIR) and are based on the Theralux platform. The Company develops ATIR101 and ATIR201, which are designed to support the patient’s newly transplanted immune system before it becomes fully functional. The Company's products address risks and limitations of hematopoietic stem cell transplantation (HSCT) in blood cancers, such as opportunistic infections, Graft-versus-Host-Disease (GVHD), cancer relapse and limited donor availability.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.